Caris data tie its AI-guided therapy recommendations to longer survival in pancreatic cancer patients.
The oncology trial matching company joins OpenAI's Select tier to pair frontier models with cancer care workflows.
Tempus's PRISM2 foundation model matches or beats rivals on diagnostic and prognostic pathology tasks.
COMPASS, a pan-cancer foundation model, outperforms 22 methods across 16 clinical cohorts by analyzing tumor transcriptomes through immune concepts.
The Series D funds targeted alpha therapy for solid tumors using AI-powered isotope targeting.